Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: A randomized phase III …
D Koeberle, DC Betticher, R Von Moos, D Dietrich… - 2013 - ascopubs.org
3503 Background: Chemotherapy plus bevacizumab is a standard option for first-line
treatment in metastatic colorectal cancer patients. We assessed whether no continuation is
non-inferior to continuation of bevacizumab after stop of first-line chemotherapy. Methods: In
an open-label, phase 3 multicenter study conducted in Switzerland, patients with
unresectable metastatic colorectal cancer having non-progressive disease after 4-6 months
of standard first-line chemotherapy plus bevacizumab were randomly assigned in a 1: 1 ratio …
treatment in metastatic colorectal cancer patients. We assessed whether no continuation is
non-inferior to continuation of bevacizumab after stop of first-line chemotherapy. Methods: In
an open-label, phase 3 multicenter study conducted in Switzerland, patients with
unresectable metastatic colorectal cancer having non-progressive disease after 4-6 months
of standard first-line chemotherapy plus bevacizumab were randomly assigned in a 1: 1 ratio …
Bevacizumab Continuation Versus No Continuation After First-Line Chemo-Bevacizumab Therapy in Patients with Metastatic Colorectal Cancer: a Phase 3 Non …
D Koeberle, D Betticher, R Von Moos… - Annals of …, 2013 - annalsofoncology.org
Background: Chemotherapy plus bevacizumab is a standard option for first-line treatment in
metastatic colorectal cancer patients. We assessed whether no continuation is non-inferior
to continuation of bevacizumab after stop of first-line chemotherapy. Methods: In an open-
label, phase 3 multicenter study conducted in Switzerland, patients with unresectable
metastatic colorectal cancer having non-progressive disease after 4-6 months of standard
first-line chemotherapy plus bevacizumab were randomly assigned in a 1: 1 ratio to …
metastatic colorectal cancer patients. We assessed whether no continuation is non-inferior
to continuation of bevacizumab after stop of first-line chemotherapy. Methods: In an open-
label, phase 3 multicenter study conducted in Switzerland, patients with unresectable
metastatic colorectal cancer having non-progressive disease after 4-6 months of standard
first-line chemotherapy plus bevacizumab were randomly assigned in a 1: 1 ratio to …
以上显示的是最相近的搜索结果。 查看全部搜索结果